The increasing availability of public data sets, such as The Cancer Genome Atlas (TCGA) and the Alzheimer s Disease Neuroimaging Initiative (ADNI), offers a transformational opportunity for insight-driven planning at all phases of the drug development life cycle. The size and scope of these publOriginal Article
You may also like
FDA Approves SpringWorks Therapeutics Treatment for...
ADVANCEMENTS IN GLP-1 ANALOG FORMULATION DEVELOPMENT:...
Axplora Announces €50 Million Investment in GLP-1...
Drug Digest: Advances in Small-Molecule Manufacturing
Navigating Drug Development: The Critical Role of...
MMS Acquires Exploristics and Its Flagship Modeling...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.